| Old Articles: <Older 6811-6820 Newer> |
|---|
 |
The Motley Fool
April 15, 2005
Rich Duprey |
The End of the Steel Boom Signs point to the end of the sector's growth cycle. Investors might want to look for a value during the downturn.   |
The Motley Fool
April 15, 2005
Rich Smith |
J2: Ready to Send What's the logic behind the large short position on J2? For the past four quarters, every quarter, J2 has beat consensus analyst estimates for its GAAP earnings growth. |
The Motley Fool
April 15, 2005
Jeff Hwang |
Cree Rebounds The LED maker posts solid results following January's earnings warning. At its current price of around $23 per share, the stock is trading at relatively attractive 20 times next year's earnings. |
The Motley Fool
April 15, 2005
Seth Jayson |
IBM's No Bellwether Stop listening to the idiotic generalizations from the press and the analysts, and find the good companies to invest in. |
The Motley Fool
April 15, 2005
Selena Maranjian |
When $500 Dinners Are Cheap Don't confuse price with value -- they're not the same thing. Find a stock priced well below its real value, and you're looking at a very promising investment. |
The Motley Fool
April 15, 2005
Rick Aristotle Munarriz |
Seed of Chucky Schwab's first quarter may seem lackluster, but there's more to the numbers than meets the eye. Now would be a good time to take a closer look at Schwab. |
The Motley Fool
April 15, 2005
Rick Aristotle Munarriz |
Apple Falls Far From the Tree Apple drops when the news merits a spike? Sir Isaac Newton would be truly perplexed. It's a growth stock, and investors need to learn that volatility cuts both ways. |
The Motley Fool
April 15, 2005
Rick Aristotle Munarriz |
IBM Sings the Blue IBM fails to live up to expectations during its seasonally quiet first-quarter showing. Investors have been patient for an excruciatingly long time. Results need to happen sooner rather than later for IBM. |
BusinessWeek
April 25, 2005
Gene G. Marcial |
Affymetrix: A Lab Boost The GeneChip can reduce the risk of adverse reactions to drugs by checking the recipient's DNA against the drug's profile. Some people are optimistic about the company's stock. |
BusinessWeek
April 25, 2005
Emily Thornton |
Lazard's IPO May Be Hazardous But the investment bank's prospectus is so mind-bending, it's hard for investors to tell |
| <Older 6811-6820 Newer> Return to current articles. |
